DK3864152T5 - Fremgangsmåder og sammensætninger til editering af rna'er - Google Patents

Fremgangsmåder og sammensætninger til editering af rna'er Download PDF

Info

Publication number
DK3864152T5
DK3864152T5 DK19870299.5T DK19870299T DK3864152T5 DK 3864152 T5 DK3864152 T5 DK 3864152T5 DK 19870299 T DK19870299 T DK 19870299T DK 3864152 T5 DK3864152 T5 DK 3864152T5
Authority
DK
Denmark
Prior art keywords
compositions
methods
rnas
editing
editing rnas
Prior art date
Application number
DK19870299.5T
Other languages
English (en)
Other versions
DK3864152T3 (da
Inventor
Wensheng Wei
Liang Qu
Zongyi Yi
Shiyou Zhu
Chunhui Wang
Zhongzheng Cao
Zhuo Zhou
Pengfei Yuan
Original Assignee
Univ Beijing
Edigene Therapeutics Beijing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70163607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3864152(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Beijing, Edigene Therapeutics Beijing Inc filed Critical Univ Beijing
Publication of DK3864152T3 publication Critical patent/DK3864152T3/da
Application granted granted Critical
Publication of DK3864152T5 publication Critical patent/DK3864152T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
DK19870299.5T 2018-10-12 2019-10-12 Fremgangsmåder og sammensætninger til editering af rna'er DK3864152T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110105 2018-10-12
CN2019082713 2019-04-15
PCT/CN2019/110782 WO2020074001A1 (en) 2018-10-12 2019-10-12 Methods and Compositions for Editing RNAs

Publications (2)

Publication Number Publication Date
DK3864152T3 DK3864152T3 (da) 2023-10-09
DK3864152T5 true DK3864152T5 (da) 2024-08-12

Family

ID=70163607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19870299.5T DK3864152T5 (da) 2018-10-12 2019-10-12 Fremgangsmåder og sammensætninger til editering af rna'er

Country Status (21)

Country Link
US (2) US20210355494A1 (da)
EP (3) EP4306116A3 (da)
JP (2) JP7252328B2 (da)
KR (1) KR102666695B1 (da)
CN (4) CN116042611A (da)
AU (2) AU2019357450B2 (da)
BR (1) BR112021006844A8 (da)
CA (1) CA3115864A1 (da)
CL (1) CL2021000880A1 (da)
CO (1) CO2021005956A2 (da)
CR (1) CR20210243A (da)
DK (1) DK3864152T5 (da)
EC (1) ECSP21033637A (da)
ES (1) ES2962434T3 (da)
IL (1) IL282191A (da)
MX (1) MX2021004187A (da)
PE (1) PE20211402A1 (da)
PH (1) PH12021550805A1 (da)
SG (1) SG11202103666PA (da)
TW (1) TW202028466A (da)
WO (1) WO2020074001A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2574769A (en) 2017-03-03 2019-12-18 Univ California RNA Targeting of mutations via suppressor tRNAs and deaminases
EP4306116A3 (en) * 2018-10-12 2024-04-17 Peking University Methods and compositions for editing rnas
EP3914261A4 (en) 2019-01-22 2023-06-28 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
KR20210129646A (ko) 2019-01-22 2021-10-28 코로 바이오, 인크. Rna-편집 올리고뉴클레오타이드 및 그의 용도
TW202043469A (zh) 2019-01-22 2020-12-01 美商科羅生物公司 Ｒｎａ編輯之寡核苷酸及其用途
KR102851101B1 (ko) * 2019-04-15 2025-08-27 에디진 테라퓨틱스(베이징) 인크. Rna를 편집하기 위한 방법 및 조성물
PE20220300A1 (es) 2019-07-12 2022-03-09 Univ Beijing Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
WO2021113270A1 (en) 2019-12-02 2021-06-10 Shape Therapeutics Inc. Therapeutic editing
IL294201A (en) 2019-12-30 2022-08-01 Edigene Therapeutics Beijing Inc A method based on leaper technology to treat mps ih and a preparation
MX2022008197A (es) 2019-12-30 2022-08-02 Edigene Therapeutics Beijing Inc Metodo para el tratamiento del sindrome de usher y composicion del mismo.
PE20230703A1 (es) * 2020-04-15 2023-04-24 Edigene Therapeutics Beijing Inc Metodo y farmaco para tratar el sindrome de hurler
CN115777020A (zh) * 2020-04-22 2023-03-10 塑造治疗公司 使用snrna组分的组合物和方法
AU2021279027A1 (en) * 2020-05-28 2022-12-08 Korro Bio, Inc. Methods and compositions for the ADAR-mediated editing of SERPINA1
WO2022007803A1 (zh) 2020-07-06 2022-01-13 博雅辑因（北京）生物科技有限公司 一种改善的rna编辑方法
CN113897359A (zh) * 2020-07-06 2022-01-07 博雅辑因（北京）生物科技有限公司 一种改善的rna编辑方法
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for editing RNA and a method for using them
EP4240338A4 (en) * 2021-01-04 2025-08-06 Univ California IN VIVO PROGRAMMABLE RNA EDITING BY RECRUITMENT OF ENDOGENOUS ADARS
US20240309368A1 (en) * 2021-01-12 2024-09-19 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas
CA3222560A1 (en) * 2021-06-15 2022-12-22 Massachusetts Institute Of Technology Deaminase-based rna sensors
WO2023278436A1 (en) * 2021-06-29 2023-01-05 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides
WO2023020574A1 (en) * 2021-08-18 2023-02-23 Peking University Engineered adar-recruiting rnas and methods of use thereof
WO2023060186A1 (en) 2021-10-07 2023-04-13 Hepatx Corporation Methods of tracking donor cells in a recipient
WO2023077138A1 (en) * 2021-10-29 2023-05-04 Duke Univeristy Compositions and systems for rna-programable cell editing and methods of making and using same
WO2023143539A1 (en) * 2022-01-28 2023-08-03 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use thereof
WO2023185231A1 (en) * 2022-04-02 2023-10-05 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use for usher syndrome
US20260021204A1 (en) * 2022-07-15 2026-01-22 Georgia Tech Research Corporation Anti-sars-cov-1 and anti-sars-cov-2 activatable rnase guide sequences
AU2023364059A1 (en) * 2022-10-18 2025-05-08 Regeneron Pharmaceuticals, Inc. Compositions and methods comprising programmable snrnas for rna editing
US12565665B2 (en) 2022-12-21 2026-03-03 Trustees Of Boston University Compositions and methods for controlled mRNA translation and stability
CN118620958A (zh) * 2023-03-08 2024-09-10 广州医科大学 一种抗原表位的制备方法
CN121152627A (zh) * 2023-03-31 2025-12-16 时夕(广州)生物科技有限公司 一种与rna编辑靶位点形成编辑底物的序列
CN118853661A (zh) * 2023-04-28 2024-10-29 时夕(广州)生物科技有限公司 编辑rna的方法、组合物及其应用
WO2024235283A1 (en) * 2023-05-16 2024-11-21 Peking University Method of modulating rna splicing
WO2025040046A1 (zh) 2023-08-18 2025-02-27 博雅缉因（北京）生物科技有限公司 体内半衰期延长的工程化t细胞及其制备方法
CN121059628A (zh) * 2024-06-03 2025-12-05 时夕(广州)生物科技有限公司 调控RNA剪接的向导agRNA
CN119505015B (zh) * 2024-11-15 2025-10-17 北京大学 一种融合蛋白及其应用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297830B1 (ko) * 2010-09-10 2013-08-19 한국생명공학연구원 신규한 ｒｎａ 결합 단백질 및 이를 이용한 무표지 마이크로 ｒｎａ 검출방법
EP4372091A3 (en) 2014-12-12 2024-07-31 Tod M. Woolf Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US10676737B2 (en) 2014-12-17 2020-06-09 Proqr Therapeutics Ii B.V. Targeted RNA editing
JP6624743B2 (ja) * 2015-07-14 2019-12-25 学校法人福岡大学 部位特異的ｒｎａ変異導入方法およびそれに使用する標的編集ガイドｒｎａならびに標的ｒｎａ−標的編集ガイドｒｎａ複合体
WO2017040477A1 (en) * 2015-08-31 2017-03-09 The University Of Chicago Composition and methods for detecting adenosine modifications
DE102015012522B3 (de) * 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Verfahren und Substanzen zur gerichteten RNA-Editierung
EP3475424A1 (en) * 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
US10941402B2 (en) * 2016-09-01 2021-03-09 Proqr Therapeutics Ii B.V. Chemically modified single-stranded RNA-editing oligonucleotides
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
GB2574769A (en) * 2017-03-03 2019-12-18 Univ California RNA Targeting of mutations via suppressor tRNAs and deaminases
AU2018234825B2 (en) 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
JP2020535802A (ja) * 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
EP4306116A3 (en) * 2018-10-12 2024-04-17 Peking University Methods and compositions for editing rnas

Also Published As

Publication number Publication date
AU2023202184B2 (en) 2025-06-12
JP7252328B2 (ja) 2023-04-04
CN116218836A (zh) 2023-06-06
CN116042611A (zh) 2023-05-02
EP3864152A4 (en) 2021-10-13
CO2021005956A2 (es) 2021-07-30
IL282191A (en) 2021-05-31
ES2962434T3 (es) 2024-03-19
MX2021004187A (es) 2021-09-08
ECSP21033637A (es) 2021-08-31
BR112021006844A8 (pt) 2023-03-21
AU2023202184A1 (en) 2023-05-04
CN113631708B (zh) 2022-05-24
AU2019357450A1 (en) 2021-06-03
CN113631708A (zh) 2021-11-09
CN115651927B (zh) 2023-06-16
JP2021534810A (ja) 2021-12-16
DK3864152T3 (da) 2023-10-09
CN115651927A (zh) 2023-01-31
BR112021006844A2 (pt) 2021-07-20
KR102666695B1 (ko) 2024-05-23
PE20211402A1 (es) 2021-08-02
EP4527931A1 (en) 2025-03-26
AU2019357450B2 (en) 2023-01-12
EP3864152A1 (en) 2021-08-18
US20210355494A1 (en) 2021-11-18
EP4306116A2 (en) 2024-01-17
WO2020074001A1 (en) 2020-04-16
PH12021550805A1 (en) 2021-10-04
CL2021000880A1 (es) 2021-12-10
SG11202103666PA (en) 2021-05-28
EP3864152B1 (en) 2023-08-16
CA3115864A1 (en) 2020-04-16
JP2023078373A (ja) 2023-06-06
EP4306116A3 (en) 2024-04-17
CR20210243A (es) 2021-10-07
KR20210076082A (ko) 2021-06-23
TW202028466A (zh) 2020-08-01
US20210310026A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
DK3864152T3 (da) Fremgangsmåder og sammensætninger til editering af rna'er
DK4104687T5 (da) Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe
IL287248A (en) Methods and preparations for editing RN" A
IL273817A (en) Preparations and methods for editing rna
EP3445407A4 (en) COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY
DK4075992T3 (da) Isoleret oleosomsammensætning og fremgangsmåde til fremstilling heraf
DK3635009T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
EP3728588A4 (en) CAS12A SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDIT OF RNA BASES
EP3823673A4 (en) ANTI-CD112R COMPOSITIONS AND METHODS
DK3897833T3 (da) Hæmmere af APOL1 og fremgangsmåder til anvendelse heraf
EP3843729A4 (en) NOVEL COMPOSITIONS AND PROCESSES
DK3880660T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
EP3382018A4 (en) DNA METHYLATION EDITING KIT AND DNA METHYLATION EDITING METHOD
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
DK4279084T3 (da) Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi
DK3302709T3 (da) Fremgangsmåder og sammensætninger til rna-guidet behandling af hiv-infektion
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3402483T3 (da) Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
DK4004022T3 (da) Materialer og fremgangsmåder til behandling af friedreichs ataksi
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK4428234T3 (da) Direkte-til-bibliotek-fremgangsmåder, systemer og sammensætninger
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer